top of page
  • Writer's pictureTaher Tarraf

Researchers are actively working on a medication to address one of the deadliest forms of cancer.

A team of Australian scientists has made a groundbreaking discovery in the fight against #pancreatic adenocarcinoma, one of the most lethal cancers.

Researchers at the Garvan Institute for Medical Research have unveiled a new drug targeting fibrous tissue within these tumors. In mouse model trials, the drug, known as PXS-5505, when combined with chemotherapy, boosted survival rates by over 35% compared to chemotherapy alone.

Pancreatic #cancer often leads to the formation of scar tissue, making it resistant to standard treatments like radiotherapy, immunotherapy, and chemotherapy. The innovative drug in this study effectively counteracts this scar tissue development.

Associate Professor Thomas Cox, Head of the Matrix & Metastasis Lab at the Garvan Institute, emphasized the significance of this discovery, stating, "The preclinical validation of this first-in-class anti-fibrotic drug represents a major milestone in our quest to overcome significant challenges in treating cancer. It brings hope to patients and their families affected by pancreatic cancer."

Typically, pancreatic cancer is diagnosed in its advanced stages, leaving chemotherapy as the primary treatment option. However, many patients develop chemotherapy resistance, partly due to the fibrous network of scar tissue that forms in and around the tumors, reducing the effectiveness of chemotherapy drugs.

0 views0 comments
bottom of page